Budgetary impact for the national health system of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement;Impacto presupuestario para el sistema nacional de salud de la prevención del tromboembolismo venoso con apixaban en pacientes sometidos a artroplastia total de rodilla o cadera

Revista Espanola de Salud Publica

Volumn 86, Issue 6, 2012, Pages 601-612

  Arrayas, Inmaculada Gómez ^a   Fernández, Carmen Suárez ^b   Cerezo, Jorge F Gómez ^c   Nicolás, Lourdes Betegón ^d   De Salas Cansado, Marina ^e   Rubio Terrés, Carlos ^f  

^a HOSPITAL RUBER INTERNACIONAL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^d BRISTOL MYERS SQUIBB   (United States)

^e PFIZER INC   (United States)

^f Health Value   (Spain)

Author keywords

Apixaban; Cost analysis; Prophylaxis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; DRUG DERIVATIVE; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; MORPHOLINE DERIVATIVE; POLYSACCHARIDE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

AGED; ARTICLE; BLEEDING; BUDGET; COST CONTROL; ECONOMICS; FEMALE; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; NATIONAL HEALTH SERVICE; SPAIN; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; BETA-ALANINE; BUDGETS; COST CONTROL; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MORPHOLINES; POLYSACCHARIDES; PULMONARY EMBOLISM; PYRAZOLES; PYRIDONES; SPAIN; STATE MEDICINE; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84873540089     PISSN: 11355727     EISSN: 16969820     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Páramo JA, Feliu J, Iglesias R, Ruiz de Gaona E, Lecumberri R. Profilaxis del tromboembolismo venoso: recomendaciones en pacientes médicos y sistema de alarma electrónica en pacientes hospitalizados. Rev Med Univ Navarra. 2006; 50: 17-23.
2. Thomas M. Venous thromboembolism - manifestations and diagnosis. Hosp Pharm. 2006; 13: 199-204.
3. Grupo Multidisciplinar para el Estudio de la Enfermedad Tromboembólica en España. Estudio sobre la enfermedad tromboembólica venosa en España. Madrid: Sociedad Española de Medicina Interna; 2006.
4. Gutiérrez J. Profilaxis tromboembólica en cirugía orto pédi ca . Disponible en URL : http://www.fesemi.org/grupos/e- tromboembolica/publicaciones/protocolos-etv/CAP.06.pdf (consulta: diciembre de 2011).
5. Samama CM, Ravaud P, Parent F, Barré J, Mertl P, Mismetti P. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost. 2007; 5: 2360-67.
6. Arcelus JI, Monreal M, Caprini JA, Guisado JG, Soto MJ, Núñez MJ, Alvárez JC; RIETE investigators. Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry. Thromb Haemost. 2008; 99: 546-51.
7. Becattini C, Lignani A, Agnelli G. New anticoagulants for the prevention of venous thromboembolism. Drug Des Devel Ther. 2010; 4: 49-60.
8. Lozano FS, Arcelus JI, Monreal M. Nuevos anticoagulantes orales. Angiología. 2010; 62: 26-32.
9. Monreal M, González-Rojas N, Vieta A, Wolowacz SE. Análisis económico de dabigatrán etexilato en prevención primaria del tromboembolismo venoso tras artroplastia de cadera o rodilla. Pharmaco Economics Spa Res Art. 2009; 6: 126-45.
10. Ficha técnica. Clexane 40 mg (4000 UI) solución inyectable en jeringa precargada. Agencia Española de Medicamentos y Productos Sanitarios. Disponible en: https://sinaem4.agemed.es/consaem/especialidad.do? metodo=verFichaWordPdf&codigo=58503&formato=pd f&formulario=FICHAS (citado diciembre de 2011).
11. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, and the ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised dou-ble-blind trial. Lancet 2010; 375: 807-15.
12. Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost 2011; 105:245-53.
13. Instituto Nacional de Estadística. Estimación de la población actual de España. Ambos sexos. 1 de abril de 2011. INEbase. Disponible en : http://www.ine.es (citado: 10 de junio de 2011).
14. Allepuz A, Serra-Suton V, Espallargues M, Sarria A. Artroplastias de cadera y rodilla en el Sistema Nacional de Salud. Rev Ortp Traumatol. 2009; 53: 290
15. Cohen A, Drost P, Marchant N, Mitchell S, Orme M, Rublee D, et al. The efficacy and safety of pharmacological prophylaxis of Venous Thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. Clin Appl Thromb Hemost. 2012 Mar [Epub ahead of print].
16. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004; 23: 3105-24.
17. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med. 1996;15: 2733-49.
18. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med. 1995;14: 2685-99.
19. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363: 2487-98.
20. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361: 594-604.
21. Huo M, Eriksson BI, Dahl OE, Kurth AA, Hantel S, Hermansson K, et al. Oral dabigatran versus.enoxapa-rin fro thromboprophylaxis after primary total hip arthroplasty: The RENOVATE-II randomised trial (abstract). Lebanon: European Hematology Association; 2010.
22. Lassen MR, Bauer KA, Eriksson BI, Turpie AG, European Pentasaccharide Elective Surgery Study Steering C. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002; 359: 1715-20.
23. Navarro-Quilis A, Castellet E, Rocha E, Paz-Jime-nez J, Planes A, Bemiparin Study Group in Knee A. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, doubleblind clinical trial. J Thromb. Haemost. 2003; 1: 425
24. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006; 114: 2374-81.
25. Planes A, Samama MM, Lensing AWA, Buller HR, Barre J, Vochelle N, et al. Prevention of deep vein thrombosis after hip replacement. Comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999; 81: 22-5.
26. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358: 2765-75.
27. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism aftertotal hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372: 31-9.
28. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358:2776-86.
29. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373: 1673-80.
30. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24: 1-9.
31. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost. 2007; 5: 2178-85.
32. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-88.
33. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719-48.
34. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997; 50: 683-91.
35. Sutton AJ, Abrams KR. Bayesian methods in metaanalysis and evidence synthesis. Stat Methods Med Res. 2001;10: 277-303.
36. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health Care Evaluation. Chichester: Wiley; 2003.
37. MRC Biostatistics Unit, Cambridge, UK. The BUGS Project. [citado diciembre de 2011]. Disponible en URL: http://www.mrcbsu.cam.ac.uk/bugs/welco- me.shtml
38. Centro de información online de medicamentos de la AEMPS-CIMA. [citado: diciembre de 2011]. Disponible en: https://sinaem4.agemed.es/consaem/ fichas-Tecnicas.do?metodo=detalleForm&version=new
39. Ministerio de Sanidad y Consumo. Norma estatal de los AP GRD V23 por cluster. Año 2009. Disponible en URL: http://www.msps.es/estadEstudios/ estadisticas/docs/NormaGRD2009/NORMA-2009-AP-GRD-V23-CLUSTER.xls (consulta: 10 de junio de 2011).
40. Base de datos de medicamentos. Consejo General de Colegios Oficiales de Farmacéuticos. (citado: noviembre de 2011).Disponible en: http://www.portal-farma.com/home.nsf
41. Montes J, González L, Amador L, Novo A, Enero M, Rey G, et al. Tratamiento domiciliario de la trombosis venosa profunda. Comparación de costes con la hospitalización convencional. An Med Interna. 2005; 22: 369-72.
42. Navarrete-Navarro P, Hart WM, Lopez-Bastida J, Christensen MC. The societal costs of intracerebral hemorrhage in Spain. Eur J Neurol. 2007; 14: 556-62.
43. Pettiti DB. Meta-analysis, Decision analysis and Cost-efectiveness analysis. Methods for quantitative synthesis in medicine. New York: Oxford University Press; 1994
44. Gómez-Cerezo JF, Gómez-Arrayás I, Suárez-Fer-nández C, Betegón-Nicolás L, de Salas-Cansado M, Rubio-Terrés C. Análisis coste-efectividad de apixa ban frente a dabigatrán en la prevención del tromboembolismo venoso en pacientes sometidos a artroplastia total de rodilla o cadera. Rev Esp Cir Ortop Traumatol. 2012. http://dx.doi.org/10.1016/j.recot.2012.07.009.
45. Suárez C, Gómez JF, Gómez I, Betegón L, de Salas-Cansado M, Rubio-Terrés C. Estudio coste-efectividad de apixaban vs enoxaparina en la prevención del tromboembolismo venoso en artroplastia de rodilla y cadera. Gac Sanit. 2012; 26: 45.